Alzheimer’s Drug Sabirnetug Fails to Improve Cognition Despite Reducing Amyloid Plaques
In a phase 2 clinical trial, the experimental drug sabirnetug successfully reduced amyloid plaques in the brain but did not improve cognitive outcomes. As a result, the developer Acumen has discontinued further development and is planning an open-label extension study. The findings highlight challenges in translating biomarker improvements into meaningful clinical benefits.
In a phase 2 clinical trial, the experimental Alzheimer’s drug sabirnetug, developed by biopharmaceutical company Acumen, demonstrated a measurable reduction in amyloid plaques in the brains of participants— a key biomarker associated with the disease. Despite this positive biological signal, the drug failed to produce any significant improvement in cognitive function among patients, as assessed through standardized clinical evaluations. This disconnect between biomarker response and clinical benefit prompted Acumen to discontinue further development of sabirnetug in its current form. The company has since announced plans for an open-label extension study, which will allow participants to continue receiving the drug outside the controlled trial setting, potentially offering long-term safety data or insights into real-world use. No specific dates, dosages, or geographic locations were included in the available information.
The failure underscores a persistent challenge in Alzheimer’s research: translating measurable biological changes into tangible improvements in patients’ daily lives. Previous efforts, such as the development and eventual withdrawal of solanezumab and aducanumab, have similarly shown that reducing amyloid plaques does not guarantee cognitive benefit. These earlier trials set a precedent for cautious optimism followed by disappointment, shaping current expectations around drug development. Acumen’s decision reflects a broader trend in the pharmaceutical indu
The failure of sabirnetug may dampen investor enthusiasm for amyloid-targeting therapies, potentially influencing funding priorities in Alzheimer’s drug development. While pharmaceutical companies continue to explore new mechanisms—such as tau protein inhibitors or anti-inflammatory approaches—this setback reinforces skepticism about the amyloid hypothesis as a standalone treatment pathway. Patients and families affected by Alzheimer’s may experience renewed frustration, especially if they had hoped for near-term breakthroughs. The broader healthcare system could see delayed access to potentially effective treatments if developers shift focus away from biomarker-driven trials. A comparable case is the 2019 withdrawal of solanezumab after phase 3 trials showed no cognitive benefit despite plaque reduction. Moving forward, regulators and researchers may place greater emphasis on multi-domain endpoints that better capture real-world functional improvements. What to watch for includes whet